AngioDynamics (NASDAQ:ANGO) Share Price Passes Above 200 Day Moving Average – Should You Sell?

AngioDynamics, Inc. (NASDAQ:ANGO)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.41 and traded as high as $10.78. AngioDynamics shares last traded at $10.33, with a volume of 356,560 shares changing hands.

Analysts Set New Price Targets

Separately, HC Wainwright increased their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Trading Down 2.5 %

The firm has a 50-day simple moving average of $10.72 and a two-hundred day simple moving average of $8.44. The company has a market capitalization of $418.01 million, a price-to-earnings ratio of -1.83 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. AngioDynamics’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) EPS. On average, sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Systematic Financial Management LP grew its position in shares of AngioDynamics by 4.6% in the fourth quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier’s stock valued at $23,093,000 after purchasing an additional 110,719 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in AngioDynamics by 10.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier’s stock valued at $13,636,000 after purchasing an additional 135,007 shares during the period. Segall Bryant & Hamill LLC grew its holdings in AngioDynamics by 55.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock valued at $12,963,000 after buying an additional 503,713 shares during the last quarter. Nuveen Asset Management LLC increased its position in AngioDynamics by 37.4% in the 4th quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier’s stock worth $11,875,000 after buying an additional 353,070 shares during the period. Finally, Royce & Associates LP increased its position in AngioDynamics by 13.5% in the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock worth $10,254,000 after buying an additional 133,312 shares during the period. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.